These findings suggest that BAG3 may represent a potential, non-invasive biomarker reflecting fibrogenic burden and a mechanistic link between genetic risk and hepatic fibrosis in MASLD. This evidence concerns the gene BAG3 and metabolic dysfunction-associated steatotic liver disease.